Company Summary - Aojing Medical (688613) reported a significant increase in sales volume of its core product "Gaojin," with a year-on-year growth of 93.54% in 2024, selling 1.4714 million cm3 compared to 760,300 cm3 in 2023 [1] - In Q1 2025, the sales volume of "Gaojin" further accelerated, achieving a remarkable growth of 174% [1] - The price of artificial bone products, including "Gaojin," decreased significantly due to centralized procurement, with prices dropping from 1,000-1,500 RMB/cm3 to 320-340 RMB/cm3, allowing more patients to access these materials [1] Industry Overview - The domestic bone repair market is in a phase of continuous expansion, with significant growth potential for artificial bone, particularly biomimetic mineralized collagen materials [3] - The market size of bone repair materials in China was approximately 2.58 billion RMB in 2023, with a projected compound annual growth rate (CAGR) of 14.5% from 2022 to 2028 [3] - Artificial bone materials are becoming the primary clinical application consumables in the bone repair field, overcoming the limitations of autologous and natural bone [3]

Core Viewpoint - The report highlights the financial performance and operational challenges faced by Aojing Medical Technology Co., Ltd. in 2024, including a significant decline in revenue and net profit due to price reductions from centralized procurement and increased competition in the medical device market [2][11]. Summary by Sections Business Performance - In 2024, the company's main business revenue was impacted by a decrease in the ex-factory price of artificial bones due to centralized procurement, leading to a net profit of -12.66 million yuan, a year-on-year decrease of 123.35% [2][11]. - The revenue from the neurosurgery product "Cerebrum" was 13.85 million yuan, down 70.07% year-on-year [2][11]. - The company reported a significant increase in sales volume of its orthopedic product "Guanjin," with a total sales volume of 1.4714 million cm³ in 2024, a 93.54% increase from 2023 [5][11]. Product Analysis - The centralized procurement led to a drop in the clinical terminal price of artificial bones from 1,000-1,500 yuan/cm³ to 320-340 yuan/cm³, which increased the accessibility of artificial bones for patients [5][11]. - The oral product "Zhibei" saw a substantial revenue increase due to new high-quality distributor partnerships, contributing 30.84 million yuan, accounting for 78.44% of its total revenue [5][16]. Regional Sales Concentration - The company's sales are primarily concentrated in East and North China, where it has established a strong presence with over 200 hospitals using its products [7][11]. - The concentration in these regions is attributed to the availability of advanced medical resources and the acceptance of innovative medical products [7][11]. Sales Expenses - Sales expenses increased significantly due to the expansion of the sales team and marketing efforts related to the centralized procurement and the acquisition of HumanTech Dental [9][11]. - The increase in travel expenses was driven by a higher number of terminal hospitals and the need for market support activities [9][11]. Financial Challenges - The company's performance turned from profit to loss due to several factors, including reduced profit margins from centralized procurement, declining neurosurgery product revenue, and increased operating costs [11][10]. - The overall gross margin for the orthopedic product "Guanjin" fell to 72.84%, a decrease of 11.03 percentage points year-on-year [10][11]. Acquisition of HumanTech Dental - The acquisition of HumanTech Dental was completed in 2024, with a goodwill of 24.62 million yuan, although the acquired company has not yet achieved profitability [20][21]. - The integration of HumanTech Dental's operations is aimed at expanding the company's market presence in the dental implant sector [21][22]. Accounts Receivable - The accounts receivable increased by 13.31% year-on-year, with the company extending credit terms to some high-quality distributors to support their sales efforts [17][19]. - The company has a bad debt provision ratio of 13.55%, indicating a cautious approach to credit risk management [17][19].

01 c 立信会计师事务所（特殊普通合伙） 关于奥精医疗科技股份有限公司 2024 年年度报告的信息披露监管 间询函的回复 信会师函字[2025]第 ZB113 号 立信会计师事务所(特殊普通合伙) 关于奥精医疗科技股份有限公司 2024 年年度报告的信息披露监管问询函的回复 信会师函字[2025]第 ZB113 号 上海证券交易所科创板公司管理部: 根据贵所出具的《关于奥精医疗科技股份有限公司 2024 年年度报告的信息 披露监管问询函》(以下简称"问询函")的有关要求,立信会计师事务所(特 殊普通合伙）(以下简称"年审会计师"或"我们")作为奥精医疗科技股份有 限公司（以下简称"奥精医疗"或"公司"）的 2024 年年度审计报告会计师事 务所,对问询函中提到的需要年审会计师发表意见的问题进行了认真核查,具体 回复内容如下: 说明:本回复报告中若出现总计数尾数与所列数值总和尾数不符的情况, 均为四舍五入所致。 问题 -- 关于主营业务与经营业绩。年报披露，（1）2024 年公司主营业务收入 20,043.09 万元,同比下滑 8.24%,其中骨科、神经外科业务收入分别同比下滑 3.83%、70.07%，口腔 ...

华泰联合证券有限责任公司 关于奥精医疗科技股份有限公司 2024 年年度报告的信息披露监管问询函 的核查意见 上海证券交易所： 根据贵所《关于奥精医疗科技股份有限公司 2024 年年度报告的信息披露监 管问询函》（上证科创公函【2025】0251 号）（以下简称"《问询函》"）要求，华 泰联合证券有限责任公司（简称"华泰联合"或"保荐机构"）作为奥精医疗科 技股份有限公司（简称"奥精医疗"、"公司"或"发行人"）首次公开发行股票 的保荐机构，对问询函中相关事项进行了核查，现将有关事项报告如下： 问题一 关于主营业务与经营业绩。年报披露，（1）2024 年公司主营业务收入 20,043.09 万元，同比下滑 8.24%，其中骨科、神经外科业务收入分别同比下滑 3.83%、70.07%，口腔业务收入同比增长 93.6%；（2）骨科业务收入下滑主要 系人工骨集采实施后出厂价格下降；（3）口腔产品"齿贝"报告期内实现收入 3,932.15 万元，同比增长 82.1%；（4）神经外科产品"颅瑞"报告期内收入 1,385.36 万元，同比下滑 70.07%；（5）公司业务收入主要分布于华东、华北；（6）公司 2024 年 ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-036 奥精医疗科技股份有限公司 关于 2024 年年度报告的信息披露监管问询函的 回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"或"奥精医疗"）于近日 收到由上海证券交易所下发的《关于奥精医疗科技股份有限公司 2024 年年度 报告的信息披露监管问询函》（上证科创公函【2025】0251 号）（以下简称《问 询函》），根据《问询函》的要求，公司与华泰联合证券有限责任公司（以下 简称"保荐机构"）和立信会计师事务所（特殊普通合伙）（以下简称"年审 会计师"），对问询函所列问题进行了认真核查并作出如下回复。 说明：本回复报告中若出现总计数尾数与所列数值总和尾数不符的情况， 均为四舍五入所致。 问题一 关于主营业务与经营业绩。年报披露，（1）2024 年公司主营业务收入 20,043.09 万元，同比下滑 8.24%，其中骨科、神经外科业务收入分别同比下滑 3.83%、70.07%，口腔业务收入同比增长 93. ...

Core Viewpoint - The company is holding a temporary shareholders' meeting on July 11, 2025, to discuss adjustments to fundraising projects and their implementation details [1][2][10]. Group 1: Meeting Procedures - The meeting will start at 14:30 and will require attendees to sign in 30 minutes prior [2][5]. - Only shareholders, directors, supervisors, senior management, and authorized personnel are allowed to attend [1]. - Voting will be conducted both on-site and online, with specific time slots for each method [3][6]. Group 2: Fundraising and Investment Projects - The company raised approximately RMB 547.67 million through an initial public offering, with a net amount of RMB 500.82 million after expenses [10]. - The company plans to adjust the implementation subject and location of certain fundraising projects, specifically canceling the involvement of its subsidiary in Jiaxing [12][14]. - New projects will include "Mineralized Collagen/Sulfate/Phosphate Calcium Self-setting Bone Cement," which aims to address the increasing incidence of bone defects [15][16]. Group 3: Project Adjustments - The "Aojing Health Technology Industrial Park Construction Project" will now be managed by Beijing Aojing Medical Device Co., Ltd. instead of Jiaxing Aojing [12][14]. - The project will cease funding for the "Artificial Skin" sub-project due to unsatisfactory progress and will focus on the new sub-project [14][16]. - The adjustments are intended to enhance project management and ensure effective use of raised funds [12][16].

证券代码：688613 证券简称：奥精医疗 奥精医疗科技股份有限公司 2025 年第一次临时股东大会 会议资料 二〇二五年七月 | | | | 2025 | 年第一次临时股东大会会议须知 | 1 | | --- | --- | --- | | 2025 | 年第一次临时股东大会会议议程 | 3 | | 2025 | 年第一次临时股东大会会议议案 | 5 | 2025 年第一次临时股东大会会议须知 为维护广大投资者的合法权益，保障股东在本次股东大会期间依法行使权 利，确保股东大会的正常秩序和议事效率，根据《公司法》《证券法》《上市公 司股东大会规则》《奥精医疗科技股份有限公司章程》《奥精医疗科技股份有限 公司股东大会议事规则》等有关规定，特制定本会议须知： 一、为保证本次大会的严肃性和正常秩序，除出席会议的股东、董事、监事、 高级管理人员、公司聘任律师及中介机构外，公司有权依法拒绝其他人员入场。 二、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 三、请出席大会的股东或其代理人或其他出席者在会议召开前 30 分钟到达 会场办理签到 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：688613 证券简称：奥精医疗 公告编号：2025-035 3.统一社会信用代码：91110115MA00D1UP6X 4.法定代表人/企业负责人：黄晚兰 5.住所：北京市大兴区中关村科技园区大兴生物医药产业基地永旺西路 26 号院 2 号楼 1 层、2 层、3 层、4 层北侧 6.生产地址：北京市大兴区永旺西路 26 号院 2 号楼 2 层 210 室、3 层 311-317 室 奥精医疗科技股份有限公司 自愿披露关于子公司获医疗器械生产许可证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）的全资子公司北京奥精医 疗器械有限责任公司近日收到北京市药品监督管理局颁发的《医疗器械生产许可 证》，现将相关情况公告如下： 一、医疗器械生产许可证具体情况 1.许可证编号：京药监械生产许 20250031 号 2.企业名称：北京奥精医疗器械有限责任公司 9.发证部门：北京市药品监督管理局 10.发证日期：2025 年 06 月 27 日 二、对公司的影响及风险提示 20 ...

Core Viewpoint - Aojing Medical (688613) is undergoing adjustments to its fundraising projects, including changes in implementation subjects and locations, which are deemed necessary for the company's development and efficiency in using raised funds [1][2][3]. Company Announcements - Aojing Medical's second supervisory board meeting approved two resolutions: one regarding the postponement of certain fundraising projects, and the other concerning adjustments to the implementation subjects and locations of these projects [1][4]. - The company will hold its first extraordinary shareholders' meeting on July 11, 2025, to review the adjustments to the fundraising projects [1][4]. Fundraising Project Adjustments - As of December 31, 2024, Aojing Medical's fundraising projects include the Aojing Health Technology Industrial Park construction and other projects, with a total planned investment of 500.82 million yuan [2][3]. - The Aojing Health Technology Industrial Park construction project has been postponed from June 30, 2025, to June 30, 2027, due to strategic adjustments and the impact of national procurement policies [3]. - The company has canceled the implementation of the project by its subsidiary in Jiaxing and will return the remaining raised funds to its dedicated account [2].